🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Adrián Mariño‐Enríquez

ORCID: 0000-0002-7680-9901
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Papers

Driven by 10 papers — median percentile 0. Top paper: “Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates”.

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2250
N/A
0.979DataRank · unranked
35 citations

Michael J. Nathenson, Emanuele Mazzola, Jia‐Ren Lin, Joanna Bagińska, Allison Nau +11 more

YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways

月刊美術(2021)10.1038/s41389-021-00327-w
N/A
0DataRank · unranked
35 citations

Meijun Z. Lundberg, Shuihao Zhu, Nacef Bahri, Anastasios Kyriazoglou, Liangliang Xu +4 more

Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas

Cancer(2021)10.1002/cncr.33542
N/A
0DataRank · unranked
35 citations

Meijun Z. Lundberg, Elizabeth G. Demicco, Joanna Przybył, Magdalena Matusiak, Frédéric Chibon +10 more

Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST

British Journal of Cancer(2022)10.1038/s41416-022-01990-5
N/A
0DataRank · unranked
27 citations

Matthew L. Hemming, Meijun Z. Lundberg, Matthew Serrata, Isabel Goldaracena, Ninning Liu +17 more

Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0998
N/A
0DataRank · unranked
12 citations

Jan Novotný, D. Gulhan, Isabella Klooster, Antuan V. Tran, Macy Kasbo +17 more

Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma

Modern Pathology(2023)10.1016/j.modpat.2023.100237
N/A
0DataRank · unranked
9 citations

Adrián Mariño‐Enríquez, Mark M. Hammer, Robert F. Padera, Lynette M. Sholl, Inga‐Marie Schaefer

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336.v1
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1

JCO Precision Oncology(2020)10.1200/po.19.00287
N/A
0DataRank · unranked
36 citations

Michael J. Nathenson, Jia‐Ren Lin, Shaolin Mei, Ziming Du, Karan Malik +8 more

A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Cancer Immunology Research(2024)10.1158/2326-6066.cir-23-1027
N/A
0DataRank · unranked
6 citations

Osama E. Rahma, Kevin Tyan, Yvonne Li, Anita Giobbie‐Hurder, Benjamin L. Schlechter +18 more